IDENIX PHARMACEUTICALS INC's ticker is IDIX and the CUSIP is 45166R204. A total of 135 filers reported holding IDENIX PHARMACEUTICALS INC in Q2 2014. The put-call ratio across all filers is 1.79 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2014 | $28,489,000 | +299.7% | 1,182,107 | 0.0% | 0.07% | +289.5% |
| Q1 2014 | $7,128,000 | +0.8% | 1,182,107 | 0.0% | 0.02% | 0.0% |
| Q4 2013 | $7,069,000 | +2.2% | 1,182,107 | -11.3% | 0.02% | -5.0% |
| Q3 2013 | $6,914,000 | +25.0% | 1,332,107 | -13.1% | 0.02% | +17.6% |
| Q2 2013 | $5,531,000 | -2.3% | 1,532,107 | -4.2% | 0.02% | -10.5% |
| Q1 2013 | $5,664,000 | – | 1,600,007 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baupost Group | 53,331,109 | $1,269,560,000 | 20.68% |
| Sarissa Capital Management LP | 2,000,000 | $48,200,000 | 16.39% |
| GLAZER CAPITAL, LLC | 981,058 | $23,643,000 | 9.35% |
| 12 West Capital Management LP | 1,431,480 | $34,499,000 | 4.42% |
| HAVENS ADVISORS LLC | 251,000 | $6,049,000 | 4.39% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 584,480 | $14,086,000 | 3.04% |
| LONGFELLOW INVESTMENT MANAGEMENT CO LLC | 500,000 | $12,050,000 | 2.26% |
| Bain Capital Public Equity Management, LLC | 3,364,623 | $81,087,000 | 1.96% |
| ANGELO GORDON & CO., L.P. | 1,000,000 | $24,100,000 | 1.88% |
| FIRST NEW YORK SECURITIES LLC /NY | 586 | $1,069,660,000 | 1.10% |